This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Angiotech Overcomes Royalty Pain

Angiotech Pharmaceuticals (ANPI) shares lifted Tuesday when the company said it met analysts' expectations for first-quarter earnings despite falling short on revenue.

On a GAAP basis, the Vancouver-based company earned $8 million, or 9 cents a share, in the quarter vs. $19.2 million, or 23 cents share, a year earlier. According to the company, the decrease was primarily due to lower royalty revenue from sales of Boston Scientific's (BSX - Get Report) drug-eluting coronary stents.

Excluding certain charges, Angiotech earned 16 cents a share, in line with analysts' estimates. Minus certain litigation expenses, the company earned 19 cents a share. Shares closed Tuesday up 12 cents, or 0.8%, at $14.82.

Revenue for the quarter came in at $41.9 million, including $39.4 million in royalties from Boston's stents. Analysts were expecting Angiotech's top line to reach $49.25 million. Boston has a licensing agreement with Angiotech to use the drug paclitaxel to coat its stents, which are heart devices used to prop open vessels cleared of plaque. The drug is used to prevent vessel reclogging.

Separately, Angiotech has closed its acquisition of American Medical Instruments Holdings for $787.9 million in cash, plus an acquisition cost of $8.2 million. Angiotech will begin reporting American Medical Instruments results as a part of its overall results starting with the second quarter.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BSX $18.27 0.00%
AAPL $130.28 0.00%
FB $79.19 0.00%
GOOG $532.11 0.00%
TSLA $250.80 0.00%

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs